GAVRETO (pralsetinib) capsules
Gavreto is a tyrosine kinase inhibitor that may be used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic). Brand Name: GAVRETO (pralsetinib) capsules, for oral use Initial U.S. Approval: 2020
Home | pralsetinib capsules
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
GAVRETO (pralsetinib) capsules
Pralsetinib is approved to treat: Non-small cell lung cancer and Thyroid cancer
GAVRETO is a kinase inhibitor indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion- positive non small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial.
Pralsetinib is a medication approved for RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive differentiated thyroid cancer (DTC) refractory to radioactive iodine (RAI) therapy. Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth. Pralsetinib was approved for medical use in the United States in September 2020, and in the European Union in November 2021.
Drug (Brand / Generic): GAVRETO/pralsetinib
Current Indications: non-small cell lung cancer
Marketed by: Blueprint Medicines Corporation
Approval Date: 2020
DOSAGE FORMS AND STRENGTHS OF GAVRETO (pralsetinib) – Capsules: 100 mg.
Find Reference Updates
Gavreto wins conditional EU approval to treat form of lung cancer -Roche
Reuters.com, Nov 2021
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ GAVRETO (pralsetinib) capsules ”. Confirmation of the order for GAVRETO (pralsetinib) capsules will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – GAVRETO
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha